Early-stage cardiovascular tech developer Ablacon said today that it closed a $21.5 million Series A financing round to support its advanced mapping system intended for use in treating atrial fibrillation.
Ablacon’s platform uses a novel algorithm and artificial intelligence to analyze and visualize the flow of action potentials within the heart to identify sources and drivers of atrial fibrillation. The electrographic flow map is intended to help physicians guide targeted catheter ablation therapy, the company said.
“The idea to leverage techniques and algorithms from computer vision to analyze electric signals in the heart is ingenious. Ablacon combines concepts from both the medical world and machine intelligence in a way that I think is very promising,” Daniel Cremers of the Technical University of Munich said in a prepared statement.
“The Ablacon system is a very promising innovation in AFib mapping. The early clinical experience indicates tremendous promise of this technology to improve our ability to treat this challenging disease,” Dr. Vivek Reddy of New York’s Icahn School of Medicine at Mount Sinai said in a press release.
The funding round was led by Ajax Health, the Wheat Ridge, Colo.-based company said. In connection with the funding round, Ajax Health CEO Duke Rohlen is joining the company as chairman and chief executive, Ablacon said.
“Since our first meeting with Ablacon, we have been impressed with the caliber of the team and the promise of the technology to improve patient care in AFib. I’m thrilled to join the team to advance this exciting project,” Rohlen said in a prepared release.
Founder and former CEO Peter Ruppersberg will stay on as prez and chief scientific officer, the company added.
“We look forward to working with Duke and his team of experienced healthcare executives to bring this technology to market,” Ruppersberg said in prepared remarks.
Funds raised in the round will be used to support advancing the company’s tech pipeline and for future clinical trials of the platform.
